Galera Therapeutics (NASDAQ:GRTX) stock is rocketing higher on Tuesday after the cancer treatment company revealed corrected results from a Phase 3 clinical trial.
According to a press release from the company, its Phase 3 ROMAN study covering the treatment of “RT-induced severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC)” with avasopasem did better than expected.
Galera Therapeutics says this has avasopasem reaching its primary endpoint of reducing the incidence of SOM. That’s a switch from the previous trial results, which didn’t have SOM reduction reaching significant levels.
Galera Therapeutics notes that the original results were wrong due to an error by a contract research organization. Fixing this error resulted in improvements for both primary and secondary endpoints.
Mel Sorensen, M.D., president and CEO of Galera Therapeutics, said this about the study results sending GRTX stock higher today.
“Given the high unmet medical need for patients with head and neck cancer who develop radiotherapy-induced severe oral mucositis, we are gratified that the Phase 3 ROMAN trial achieved statistical significance on the primary endpoint after the correction of the statistical programming error.”
With today’s surprising news comes a boost in trading for GRTX stock. That has some 187 million shares on the move as of this writing. That’s a massive jump from the company’s daily average trading volume of about 3 million units.
GRTX stock is up 117.7% as of Tuesday morning.
Investors looking for more stock market news today will want to keep reading!
InvestorPlace is home to all the latest stock coverage traders are looking for. A few examples include what’s happening with Mind Technology (NASDAQ:MIND), BitNile (NYSE:NILE), and Alzamend Neuro (NASDAQ:ALZN) shares today. You can find all of that info by checking out the links below!
More Stock Market News for Tuesday
- MIND Stock: The U.S. Navy Deal That Has Mind Technology Shares Surging Today
- NILE Stock: 9 Things to Know as Ault Global’s BitNile Starts Trading Today
- ALZN Stock Alert: What Is Going on With Alzamend Neuro Today?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
